Literature DB >> 21933023

Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes.

Carmen Mariana Aanei1, Pascale Flandrin, Florin Zugun Eloae, Eugen Carasevici, Denis Guyotat, Eric Wattel, Lydia Campos.   

Abstract

Myelodysplastic syndromes (MDSs) are clonal disorders of hematopoietic stem cells (HSCs) characterized by ineffective hematopoiesis. MDSs are responsible for 1 or several peripheral cytopenias. The evidence accumulated in recent years demonstrates that in addition to HSC defects, a particular role is also played by stromal microenvironment dysfunctions, which mediate the direct contact with hematopoietic precursor cells (HPCs). These interactions help regulate different adhesion-related processes, such as progenitor cell proliferation, apoptosis, clonogenic growth, and maintenance in in vitro cultures. As previously reported, these interactions are responsible for altering the microenvironment in MDS. Herein, we present a novel selection protocol for obtaining a standards-compliant mesenchymal stromal cell (MSC) preparation. This method allowed us to comparatively analyze 2 subpopulations of bone marrow MSCs (BM-MSCs) in terms of their adhesion profiles and growth abilities: BM-MSCs selected from MDS settings and their normal counterparts. Functional assays revealed that the MSCs from MDS are intrinsically pathological, thus showing a continuous decline of proliferation and a reduced clonogenic capacity during 14 days of culture and in the absence of signals from hematopoietic cells. The MSC growth defects were significantly correlated with decreases in CD44 adhesion molecules and CD49e (α5-integrin).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21933023      PMCID: PMC3376465          DOI: 10.1089/scd.2011.0390

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  36 in total

1.  [Expression of SDF-1 gene in bone marrow mesenchymal stem cells of patients with myelodysplastic syndrome].

Authors:  Yi-Zhuo Zhang; Wan-Ming DA
Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi       Date:  2006-04

2.  In vitro study of stromal cell defects in myelodysplastic syndromes.

Authors:  Delphine Boudard; Annie Viallet; Simone Piselli; Denis Guyotat; Lydia Campos
Journal:  Haematologica       Date:  2003-07       Impact factor: 9.941

3.  Markers distinguishing mesenchymal stem cells from fibroblasts are downregulated with passaging.

Authors:  Svetlana Halfon; Natalie Abramov; Borislava Grinblat; Irene Ginis
Journal:  Stem Cells Dev       Date:  2010-10-26       Impact factor: 3.272

4.  Human mesenchymal stromal cells regulate initial self-renewing divisions of hematopoietic progenitor cells by a beta1-integrin-dependent mechanism.

Authors:  Sandra Gottschling; Rainer Saffrich; Anja Seckinger; Ulf Krause; Kerstin Horsch; Katrin Miesala; Anthony D Ho
Journal:  Stem Cells       Date:  2006-11-16       Impact factor: 6.277

5.  Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue.

Authors:  Susanne Kern; Hermann Eichler; Johannes Stoeve; Harald Klüter; Karen Bieback
Journal:  Stem Cells       Date:  2006-01-12       Impact factor: 6.277

6.  Adhesion of human hematopoietic progenitor cells to mesenchymal stromal cells involves CD44.

Authors:  Wolfgang Wagner; Frederik Wein; Christoph Roderburg; Rainer Saffrich; Anke Diehlmann; Volker Eckstein; Anthony D Ho
Journal:  Cells Tissues Organs       Date:  2007-12-21       Impact factor: 2.481

Review 7.  Human bone marrow mesenchymal stem cells in vivo.

Authors:  E Jones; D McGonagle
Journal:  Rheumatology (Oxford)       Date:  2007-11-06       Impact factor: 7.580

8.  The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice.

Authors:  Ryang Hwa Lee; Min Jeong Seo; Andrey A Pulin; Carl A Gregory; Joni Ylostalo; Darwin J Prockop
Journal:  Blood       Date:  2008-09-25       Impact factor: 22.113

Review 9.  Mesenchymal stem cells.

Authors:  Brenton Short; Nathalie Brouard; Teresa Occhiodoro-Scott; Anand Ramakrishnan; Paul J Simmons
Journal:  Arch Med Res       Date:  2003 Nov-Dec       Impact factor: 2.235

10.  Physiological roles for ecto-5'-nucleotidase (CD73).

Authors:  Sean P Colgan; Holger K Eltzschig; Tobias Eckle; Linda F Thompson
Journal:  Purinergic Signal       Date:  2006-06-01       Impact factor: 3.765

View more
  25 in total

Review 1.  The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Authors:  Irene M Ghobrial; Alexandre Detappe; Kenneth C Anderson; David P Steensma
Journal:  Nat Rev Clin Oncol       Date:  2018-01-09       Impact factor: 66.675

Review 2.  The inflammatory microenvironment in MDS.

Authors:  Lili Yang; Yaqin Qian; Erika Eksioglu; Pearlie K Epling-Burnette; Sheng Wei
Journal:  Cell Mol Life Sci       Date:  2015-02-08       Impact factor: 9.261

3.  Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide.

Authors:  Ruben A Ferrer; Manja Wobus; Catrin List; Rebekka Wehner; Claudia Schönefeldt; Barbara Brocard; Brigitte Mohr; Martina Rauner; Marc Schmitz; Maik Stiehler; Gerhard Ehninger; Lorenz C Hofbauer; Martin Bornhäuser; Uwe Platzbecker
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

4.  Down-regulation of Dicer1 promotes cellular senescence and decreases the differentiation and stem cell-supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome.

Authors:  Youshan Zhao; Dong Wu; Chengming Fei; Juan Guo; Shuncheng Gu; Yang Zhu; Feng Xu; Zheng Zhang; Lingyun Wu; Xiao Li; Chunkang Chang
Journal:  Haematologica       Date:  2014-10-31       Impact factor: 9.941

5.  Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients.

Authors:  Carlos Santamaría; Sandra Muntión; Beatriz Rosón; Belén Blanco; Olga López-Villar; Soraya Carrancio; Fermín M Sánchez-Guijo; María Díez-Campelo; Stela Alvarez-Fernández; María E Sarasquete; Javier de las Rivas; Marcos González; Jesús F San Miguel; María Consuelo Del Cañizo
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

6.  Myeloid malignancies and the microenvironment.

Authors:  Claudia Korn; Simón Méndez-Ferrer
Journal:  Blood       Date:  2016-11-15       Impact factor: 22.113

7.  Inhibition of WNT signaling in the bone marrow niche prevents the development of MDS in the Apcdel/+ MDS mouse model.

Authors:  Angela Stoddart; Jianghong Wang; Chunmei Hu; Anthony A Fernald; Elizabeth M Davis; Jason X Cheng; Michelle M Le Beau
Journal:  Blood       Date:  2017-03-27       Impact factor: 22.113

Review 8.  Myelodysplastic syndromes: revisiting the role of the bone marrow microenvironment in disease pathogenesis.

Authors:  Marc H G P Raaijmakers
Journal:  Int J Hematol       Date:  2012-01-06       Impact factor: 2.490

9.  Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell-cell adhesion.

Authors:  Fernanda Marconi Roversi; Matheus Rodrigues Lopes; João Agostinho Machado-Neto; Ana Leda F Longhini; Adriana da Silva Santos Duarte; Mariana Ozello Baratti; Bruna Palodetto; Flávia Adolfo Corrocher; Fernando Vieira Pericole; Paula de Melo Campos; Patricia Favaro; Fabiola Traina; Sara Teresinha Olalla Saad
Journal:  Stem Cells Dev       Date:  2014-02-18       Impact factor: 3.272

Review 10.  Revisiting the hallmarks of cancer.

Authors:  Yousef Ahmed Fouad; Carmen Aanei
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.